Zhang Hui Appointed Corporate Vice President of Novo Nordisk China, Overseeing Diabetes Business Unit

On the afternoon of October 26, Zhou Xiaping, Senior Vice President of Novo Nordisk and President of Greater China, announced to employees that Zhang Hui would join Novo Nordisk China as Corporate Vice President (CVP) effective November 1. He will become a member of the Executive Team (ET) for Novo Nordisk Greater China, oversee the Diabetes Care business unit, and report directly to Zhou Xiaping.

Prior to joining Novo Nordisk, Zhang Hui served at AstraZeneca. When Zhang Hui joined AstraZeneca in 2015, Da Mi had previously introduced his professional background to colleagues. Zhang Hui was formerly an endocrinologist and oversaw the metabolic disease portfolio during his tenure at Novartis. His current move to Novo Nordisk marks a return to his area of expertise.

Zhang Hui graduated from Beijing Medical University (now Peking UniversityMedicineDepartment of Clinical Medicine. After graduation, he joined Beijing China-Japan Friendship Hospital in 1990 and became an endocrinologist.

After working as a physician at a hospital for five years, she joined BD China, which had recently entered the Chinese market. Four years later, she moved to Merck Sharp & Dohme (MSD) China, where she has been engaged in sales and brand management.

In 2004, Zhang Hui joined Novartis Pharmaceuticals (China), where he successfully held multiple marketing management positions. After completing an international rotation at the corporate headquarters in 2010, he successively served as Senior Marketing Director for the Hypertension and Metabolism franchise at Novartis China, General Manager of Novartis Shanghai, and Head of the Marketing & Sales Operations and Key Accounts departments.

On July 1, 2015, AstraZeneca China split its largest business unit, the Gastrointestinal, Respiratory and Anesthesia Business Unit, into two separate units: the Gastrointestinal, Anesthesia and Anti-infectives Business Unit (GAA) and the Respiratory, Inflammation and Autoimmunity Business Unit (RIA). Zhang Hui was appointed as the head of RIA upon joining AstraZeneca China (for details, see historical messages from MRCLUB). On November 26, 2017, Zhang Hui was appointed Vice President, Acceleration of Respiratory Business, within AstraZeneca’s International Business Unit. Chen Penggen returned to AstraZeneca to succeed Zhang Hui as head of RIA. (Chen, also a physician by training, previously served as Sales and Marketing Director for AstraZeneca China’s Brilinta team. He left AstraZeneca in early 2017 to join Takeda China as Head of Commercial Development and Strategy. For further details, please refer to historical messages from MRCLUB.)

Last week, Dami shared with readers that Zhou Xiaping, Senior Vice President of Novo Nordisk and President of Greater China, had adjusted the organizational structure, announcing that as of January 1, 2019, Novo Nordisk China would operate with two sales teams: the newly established Emerging Business Unit and the existing Diabetes Care Unit. Gao Kun was promoted to Vice President of the newly formed Emerging Business Unit. The position formerly held by He Weicong in the Diabetes Care Unit has remained vacant since his departure, with the industry closely watching for his successor. Last week, Novo Nordisk announced that the appointment would be revealed soon (see: “Expansion of Operations in China: Major Organizational Restructuring at Novo Nordisk China!”).

Today, the specific appointment was finally announced. Zhou Xiaping stated that Zhang Hui’s joining would bring significant value to Novo Nordisk China.

Source:PharmaceuticalsRepresentative

Author: Dami